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patientsTable 1 Blood type tests before and after induction
chemotherapy.
Therapy Forward type Reverse type Saliva
testAnti-
A
Anti-
B
Anti-
A,B
Anti-
D
A-cell B-cell
Patient
A
Before neg neg neg 4þ neg 4þ A H
After 4þ neg 4þ 4þ neg 4þ A H
Patient Before  4þ 4þ 4þ neg neg A B HDear Editor,
The ABO blood group is the most useful and important
system in transfusion medicine. However, ABO blood group
discrepancies have been noticed in normal blood donors
and patients with malignancies, especially hematologic
malignancies [1,2]. Here, we report two cases of acute
myelogenous leukemia (AML) patients who showed a
discrepancy in the ABO blood test using forward and reverse
methods for the diagnosis.
Patient A, a 28-year-old male, was diagnosed with AML
in April 2015. No blood group discrepancy was found with
either A or B antigen in forward typing; however there was
a 4þ agglutination with B cell without any agglutination
with A cell in reverse typing (Table 1). The patient’s history
showed Aþ blood type in blood donation. To investigate
further, the fresh sample was tested by tube method with
similar results. The auto-control, direct Coombs’ and indi-
rect Coombs’ tests were performed with negative results.
Further analysis by saliva test confirmed that the patient
has Aþ blood type. Cytogenetic study showed a normal
karyotype without FLT3, NPM1 mutation. He received
induction chemotherapy with idarubicine and cytarabine,
and complete remission was achieved. A recheck of the
blood type for this patient was done in remission status and
it was found that the discrepancy had disappeared.
Patient B was a 48-year-old man who was diagnosed with
AML. Blood type was also performed with forward typing
which showed an anti-A weak trace reaction and anti-B 4þ
agglutination. There was no agglutination with A cell and B
cell in reverse typing. The patient’s blood type was re-
ported as AB positive in the past. We ran the same protocol
as patient A. The fresh sample was tested by tube method
which resulted in 1þ reaction with anti-A after incubation
at room temperature for 30 minutes. The auto-control,
direct Coombs’ and indirect Coombs’ tests, were per-
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tually disappeared after the patient achieved complete
remission with chemotherapy.
Alteration of ABH antigens in hematologic malignancies
was first reported in 1957 by van Loghem et al. [3] who
described very weak A antigen expression on the red cells
of a patient with acute myeloid leukemia, but had previ-
ously shown normal A antigen expression. Similar to our
cases, the loss of A, B, or H antigens from the surface of red
blood cells was reported and the discrepancy restored
when the diseases were under control. Some reports
showed that hematologic malignancies had the potential to
alter the phenotype of ABH antigen expression due to ge-
netic instability. One mechanism was the inactivation of H
transferase encoded at 19q13 which would result in a
decrease of H substance, which in turn would decrease A
and/or B substance and cause a less frequent expression of
these two antigens [4].
It was concluded that the discrepancy in these two cases
were due to decreased expression of A antigens on the
surface of red blood cells secondary to acute myeloid leu-
kemia. The discrepancy was resolved after the disease was
successfully treated. Further knowledge is warranted for a
better understanding of these phenomena.B After 4þ 4þ 4þ 4þ neg neg A B H
negZ negative.
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